|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||305.36 g/mol|
|3D model (Jmol)|
Cetraxate (INN) is an oral gastrointestinal medication which has a cytoprotective effect. Double-blind clinical trials in patients with gastric ulcer compared the effects of cetraxate with those of the drug gefarnate, a common standard drug treatment for gastric ulcer. Endoscopic examinations of patients treated with cetraxate showed cure rates of 28% after 4 weeks, 61% after 8 weeks, and 73% after 12 weeks of treatment, significantly higher than cure rates seen with gefarnate at both 8 and 12 weeks.
- Kurebayashi Y, Ikeda T, Osada Y (January 1988). "Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats". Jpn. J. Pharmacol. 46 (1): 17–25. PMID 3367546. doi:10.1254/jjp.46.17.
- Ishimori A, Yamagata S, Taima T (1979). "Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (Cetraxate) on peptic ulcer. Multi-center clinical study". Arzneimittelforschung. 29 (10): 1625–32. PMID 391240.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|